, Volume 185, Issue 4, pp 524–528 | Cite as

Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia

  • Sebastian WaltherEmail author
  • Richard Mahlberg
  • Uta Eichmann
  • Dieter Kunz
Original Investigation



Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects.


The aim of the study was to measure the effect of the cannabinoid dronabinol on nocturnal motor activity.


In an open-label pilot study, six consecutive patients in the late stages of dementia and suffering from circadian and behavioral disturbances—five patients with Alzheimer’s disease and one patient with vascular dementia—were treated with 2.5 mg dronabinol daily for 2 weeks. Motor activity was measured objectively using actigraphy.


Compared to baseline, dronabinol led to a reduction in nocturnal motor activity (P=0.028). These findings were corroborated by improvements in Neuropsychiatric Inventory total score (P=0.027) as well as in subscores for agitation, aberrant motor, and nighttime behaviors (P<0.05). No side effects were observed.


The study suggests that dronabinol was able to reduce nocturnal motor activity and agitation in severely demented patients. Thus, it appears that dronabinol may be a safe new treatment option for behavioral and circadian disturbances in dementia.


Actigraphy Behavioral disturbances Dementia Dronabinol Nighttime agitation 



This study complied with current regulations in the Federal Republic of Germany, where it was conducted.


  1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DCGoogle Scholar
  2. Ancoli-Israel S, Clopton P, Klauber MR, Fell R, Mason W (1997) Use of wrist activity for monitoring sleep/wake in demented nursing-home patients. Sleep 20:24–27PubMedGoogle Scholar
  3. Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, O’Brien JT (2004) A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 65:114–119PubMedCrossRefGoogle Scholar
  4. Breivogel CS, Childers SR (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5:417–431CrossRefPubMedGoogle Scholar
  5. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13–16CrossRefPubMedGoogle Scholar
  6. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314PubMedGoogle Scholar
  7. Doody R, Stevens J, Beck C, Dubinsky R, Kaye J, Gwyther L, Mohs R, Thal LJ, Whitehouse P, DeKosky ST, Cummings JL (2001) Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 56:1154–1166PubMedGoogle Scholar
  8. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  9. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360CrossRefPubMedGoogle Scholar
  10. Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C (2001) Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 56:M693–M699PubMedGoogle Scholar
  11. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R (1999) Natural history of behavioural changes and psychiatric symptoms in Alzheimer’s disease. A longitudinal study. Br J Psychiatry 174:39–44PubMedCrossRefGoogle Scholar
  12. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202CrossRefPubMedGoogle Scholar
  13. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA (2004) Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329:75–79CrossRefPubMedGoogle Scholar
  14. Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R (2004) Melatonin treatment of day–night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 24:456–459CrossRefPubMedGoogle Scholar
  15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedGoogle Scholar
  16. Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003a) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384–388CrossRefPubMedGoogle Scholar
  17. Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003b) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459–465PubMedCrossRefGoogle Scholar
  18. Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani PJ (2003) Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 26:943–947PubMedGoogle Scholar
  19. Ramirez BG, Blazquez C, Gomez dP, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 23:1904–1913Google Scholar
  20. Sclan SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychogeriatr 4(Suppl 1):55–69CrossRefPubMedGoogle Scholar
  21. Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329:253CrossRefPubMedGoogle Scholar
  22. Tariot PN (1999) Treatment of agitation in dementia. J Clin Psychiatry 60(Suppl 8):11–20PubMedGoogle Scholar
  23. Tariot PN, Profenno LA, Ismail MS (2004) Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 65(Suppl 11):11–15PubMedGoogle Scholar
  24. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16–21CrossRefPubMedGoogle Scholar
  25. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 12:913–919CrossRefPubMedGoogle Scholar
  26. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (2001) Sundowning and circadian rhythms in Alzheimer’s disease. Am J Psychiatry 158:704–711CrossRefPubMedGoogle Scholar
  27. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678–682CrossRefPubMedADSGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Sebastian Walther
    • 1
    • 2
    Email author
  • Richard Mahlberg
    • 1
  • Uta Eichmann
    • 1
  • Dieter Kunz
    • 1
  1. 1.Department of Psychiatry and PsychotherapyCharité Universitätsmedizin Berlin, Campus Charité Mitte (PUK)BerlinGermany
  2. 2.Psychiatric Services (UPD)University of BernBernSwitzerland

Personalised recommendations